These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 20564083

  • 1. A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
    Weber JS, Samlowski WE, Gonzalez R, Ribas A, Stephenson J, O'Day S, Sato T, Dorr R, Grenier K, Hersh E.
    Cancer; 2010 Aug 01; 116(15):3683-91. PubMed ID: 20564083
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
    Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.
    Chemotherapy; 2009 Aug 01; 55(4):221-7. PubMed ID: 19451711
    [Abstract] [Full Text] [Related]

  • 3. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE, Bedikian A, Ring S, Kim KB, Hwu WJ, Gerber DL, Homsi J, Hwu P.
    Am J Clin Oncol; 2009 Oct 01; 32(5):509-14. PubMed ID: 19506454
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of imexon in patients with advanced malignancy.
    Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R.
    J Clin Oncol; 2007 May 01; 25(13):1779-84. PubMed ID: 17470869
    [Abstract] [Full Text] [Related]

  • 5. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
    McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E.
    J Clin Oncol; 2008 May 01; 26(13):2178-85. PubMed ID: 18445842
    [Abstract] [Full Text] [Related]

  • 6. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy.
    Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A.
    Melanoma Res; 2010 Dec 01; 20(6):501-6. PubMed ID: 20859231
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Dec 01; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 11. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
    Hersh EM, O'Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, Clawson AA, Gonzalez R.
    Cancer; 2010 Jan 01; 116(1):155-63. PubMed ID: 19877111
    [Abstract] [Full Text] [Related]

  • 12. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
    Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, Kirkwood JM, Haluska FG, Oblimersen Melanoma Study Group.
    J Clin Oncol; 2006 Oct 10; 24(29):4738-45. PubMed ID: 16966688
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 14. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 15. A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma.
    O'Neill PA, Butt M, Eswar CV, Gillis P, Marshall E.
    Melanoma Res; 2006 Jun 20; 16(3):245-8. PubMed ID: 16718271
    [Abstract] [Full Text] [Related]

  • 16. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
    Hauschild A, Garbe C, Stolz W, Ellwanger U, Seiter S, Dummer R, Ugurel S, Sebastian G, Nashan D, Linse R, Achtelik W, Mohr P, Kaufmann R, Fey M, Ulrich J, Tilgen W.
    Br J Cancer; 2001 Apr 20; 84(8):1036-42. PubMed ID: 11308250
    [Abstract] [Full Text] [Related]

  • 17. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
    Pyrhönen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, Tarkkanen A, Kivelä T.
    Cancer; 2002 Dec 01; 95(11):2366-72. PubMed ID: 12436444
    [Abstract] [Full Text] [Related]

  • 18. Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
    O'Day S, Gonzalez R, Lawson D, Weber R, Hutchins L, Anderson C, Haddad J, Kong S, Williams A, Jacobson E.
    J Clin Oncol; 2009 Nov 10; 27(32):5452-8. PubMed ID: 19826135
    [Abstract] [Full Text] [Related]

  • 19. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C.
    Clin Cancer Res; 2011 Dec 15; 17(24):7732-42. PubMed ID: 22028492
    [Abstract] [Full Text] [Related]

  • 20. Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.
    McClay EF, Mastrangelo MJ, Bellet RE, Berd D.
    Cancer Treat Rep; 1987 May 15; 71(5):465-9. PubMed ID: 3567970
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.